Patents by Inventor Takahiro Sugimoto

Takahiro Sugimoto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NITROGEN-CONTAINING HETEROCYCLIC COMPOUND
    Publication number: 20210009572
    Abstract: The present invention provides a compound having a cholinergic muscarinic Ml receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.
    Type: Application
    Filed: September 30, 2020
    Publication date: January 14, 2021
    Inventors: Masami YAMADA, Shinkichi SUZUKI, Takahiro SUGIMOTO, Minoru NAKAMURA, Hiroki SAKAMOTO, Makoto KAMATA
  • Nitrogen-containing heterocyclic compound
    Patent number: 10865200
    Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.
    Type: Grant
    Filed: December 4, 2018
    Date of Patent: December 15, 2020
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Masami Yamada, Shinkichi Suzuki, Takahiro Sugimoto, Minoru Nakamura, Hiroki Sakamoto, Makoto Kamata
  • HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
    Publication number: 20200385346
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: August 2, 2018
    Publication date: December 10, 2020
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Tatsuhiko FUJIMOTO, Kentaro RIKIMARU, Koichiro FUKUDA, Hiromichi SUGIMOTO, Takahiro MATSUMOTO, Yuichi KAJITA, Satoshi MIKAMI, Yuhei MIYANOHANA, Tatsuki KOIKE, Masaki DAINI, Masaki OGINO, Kohei TAKEUCHI, Tohru MIYAZAKI, Yoshiteru ITO, Norihito TOKUNAGA, Takahiro SUGIMOTO, Tsuneo ODA, Yasutaka HOASHI, Yasushi HATTORI, Keisuke IMAMURA
  • METHOD, SERVER, PROGRAM, AND TERMINAL FOR GENERATING INFORMATION RELATING TO ELECTRICAL OUTPUT OF SOLAR GENERATOR
    Publication number: 20200321781
    Abstract: A method includes acquiring weather information relating to at least one of physical quantities including insolation, cloudiness, and humidity; performing a rating scale assessment of the weather information based on a predetermined threshold value; predicting an electrical output of a solar generator; performing a rating scale assessment of the electrical output of the solar generator based on a standard electrical output of the solar generator; and generating information indicating an assessment value obtained in the performing of the rating scale assessment of the weather information, and an assessment value obtained in the performing of the rating scale assessment of the electrical output.
    Type: Application
    Filed: May 16, 2017
    Publication date: October 8, 2020
    Applicants: Panasonic Intellectual Property Management Co., Ltd., Panasonic Intellectual Property Management Co., Ltd.
    Inventors: Takahiro SUGIMOTO, Kotaro SAKATA, Kazuya ITO, Takaaki YOSHIHARA, Takashi TORII
  • HETEROCYCLIC COMPOUND AND USE THEREOF
    Publication number: 20200247747
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: January 30, 2020
    Publication date: August 6, 2020
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Yasushi Hattori, Yuhei Miyanohana, Yuichi Kajita, Tatsuki Koike, Yasutaka Hoashi, Norihito Tokunaga, Alexander Martin Pawliczek, Tsuneo Oda, Tohru Miyazaki, Yoshiteru Ito, Kohei Takeuchi, Keisuke Imamura, Takahiro Sugimoto
  • HETEROCYCLIC COMPOUND AND USE THEREOF
    Publication number: 20200207715
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: March 6, 2020
    Publication date: July 2, 2020
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Yuichi Kajita, Yuhei MIYANOHANA, Tatsuki KOIKE, Kohei TAKEUCHI, Yoshiteru ITO, Norihito TOKUNAGA, Takahiro SUGIMOTO, Tohru MIYAZAKI, Tsuneo ODA, Yasutaka HOASHI, Yasushi HATTORI, Keisuke IMAMURA
  • HETEROCYCLIC COMPOUND AND USE THEREOF
    Publication number: 20200207734
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: August 2, 2018
    Publication date: July 2, 2020
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Yuichi KAJITA, Satoshi MIKAMI, Yuhei MIYANOHANA, Tatsuki KOIKE, Masaki DAINI, Norio OYABU, Masaki OGINO, Kohei TAKEUCHI, Yoshiteru ITO, Norihito TOKUNAGA, Takahiro SUGIMOTO, Tohru MIYAZAKI, Tsuneo ODA, Yasutaka HOASHI, Yasushi HATTORI, Keisuke IMAMURA
  • SEMICONDUCTOR MEMORY DEVICE
    Publication number: 20200202954
    Abstract: According to one embodiment, a semiconductor memory device includes: a memory cell array; a conversion circuit; a data bus; a first buffer and a second buffer; and a third buffer. The data bus includes a first wiring part extending along a first direction. The first buffer and the second buffer are separate from each other. The first to third buffers are at different positions along the first direction.
    Type: Application
    Filed: September 5, 2019
    Publication date: June 25, 2020
    Applicant: TOSHIBA MEMORY CORPORATION
    Inventors: Hiromi NORO, Yusuke OCHI, Takahiro SUGIMOTO, Naoaki KANAGAWA
  • SEMICONDUCTOR DEVICE AND METHOD FOR MANUFACTURING THE SAME
    Publication number: 20200127081
    Abstract: A semiconductor device includes a first semiconductor layer that is an electrically-conductive polycrystalline semiconductor layer and a second semiconductor layer on the first semiconductor layer. The second semiconductor layer is an electrically-conductive polycrystalline semiconductor layer having a smaller average grain size than the first semiconductor layer. A plurality of electrode layers are stacked on the second semiconductor layer at intervals in a first direction. A third semiconductor layer extends in the first direction through the first semiconductor layer, the second semiconductor layer, and each of the electrode layers and contacts the second semiconductor layer. A charge storage layer is between the plurality of electrode layers and the third semiconductor layer.
    Type: Application
    Filed: August 23, 2019
    Publication date: April 23, 2020
    Inventors: Takashi ISHIDA, Takahiro SUGIMOTO, Hiroshi KANNO, Tatsuya OKAMOTO
  • Heterocyclic compound and use thereof
    Patent number: 10584097
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Grant
    Filed: September 20, 2019
    Date of Patent: March 10, 2020
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Yuichi Kajita, Yuhei Miyanohana, Tatsuki Koike, Kohei Takeuchi, Yoshiteru Ito, Norihito Tokunaga, Takahiro Sugimoto, Tohru Miyazaki, Tsuneo Oda, Yasutaka Hoashi, Yasushi Hattori, Keisuke Imamura
  • Quinazolinone and benzotriazinone compounds with cholinergic muscarinin M1 receptor positive allosteric modulator activity
    Patent number: 10548899
    Abstract: The present invention provides a compound which has a cholinergic muscarinic M1 receptor positive allosteric modulator activity and may be useful as a medicament such as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, Lewy body dementia and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. In the formula (I), each symbol is as described in the attached specification.
    Type: Grant
    Filed: October 19, 2016
    Date of Patent: February 4, 2020
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Takahiro Sugimoto, Shinkichi Suzuki, Hiroki Sakamoto, Masami Yamada, Minoru Nakamura, Makoto Kamata, Kenichiro Shimokawa, Masaki Ogino, Eiji Kimura, Masataka Murakami, Takuto Kojima, Jinichi Yonemori
  • HETEROCYCLIC COMPOUND AND USE THEREOF
    Publication number: 20200017444
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: September 20, 2019
    Publication date: January 16, 2020
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Yuichi KAJITA, Satoshi MIKAMI, Yuhei MIYANOHANA, Tatsuki KOIKE, Masaki DAINI, Norio OYABU, Masaki OGINO, Kohei TAKEUCHI, Yoshiteru ITO, Norihito TOKUNAGA, Takahiro SUGIMOTO, Tohru MIYAZAKI, Tsuneo ODA, Yasutaka HOASHI, Yasushi HATTORI, Keisuke IMAMURA
  • Isoindoline-1-one derivatives as cholinergic muscarinic M1 receptor positive alloesteric modulator activity for the treatment of Alzheimers disease
    Patent number: 10457670
    Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.
    Type: Grant
    Filed: December 4, 2017
    Date of Patent: October 29, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Masami Yamada, Shinkichi Suzuki, Takahiro Sugimoto, Minoru Nakamura, Hiroki Sakamoto, Makoto Kamata
  • Heterocyclic compound
    Patent number: 10428056
    Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.
    Type: Grant
    Filed: August 27, 2018
    Date of Patent: October 1, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Takahiro Sugimoto, Shinkichi Suzuki, Hiroki Sakamoto, Masami Yamada, Minoru Nakamura, Makoto Kamata, Kenichiro Shimokawa, Masataka Murakami, Jinichi Yonemori, Takuto Kojima
  • Heterocyclic compound and use thereof
    Patent number: 10428023
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: October 1, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Yuichi Kajita, Yuhei Miyanohana, Tatsuki Koike, Kohei Takeuchi, Yoshiteru Ito, Norihito Tokunaga, Takahiro Sugimoto, Tohru Miyazaki, Tsuneo Oda, Yasutaka Hoashi, Yasushi Hattori, Keisuke Imamura
  • 2,3-DIHYDRO-4H-1,3-BENZOXAZIN-4-ONE DERIVATIVES AS MODULATORS OF CHOLINERGIC MUSCARINIC M1 RECEPTOR
    Publication number: 20190248776
    Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.
    Type: Application
    Filed: April 25, 2019
    Publication date: August 15, 2019
    Inventors: Takahiro SUGIMOTO, Shinkichi SUZUKI, Hiroki SAKAMOTO, Masami YAMADA, Minoru NAKAMURA, Makoto KAMATA, Kenichiro SHIMOKAWA, Masaki OGINO, Eiji KIMURA, Masataka MURAKAMI, Jinichi YONEMORI, Takuto KOJIMA
  • NITROGEN-CONTAINING HETEROCYCLIC COMPOUND
    Publication number: 20190241547
    Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.
    Type: Application
    Filed: December 4, 2018
    Publication date: August 8, 2019
    Inventors: Masami YAMADA, Shinkichi SUZUKI, Takahiro SUGIMOTO, Minoru NAKAMURA, Hiroki SAKAMOTO, Makoto KAMATA
  • 2,3-dihydro-4H-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic M1 receptor
    Patent number: 10323027
    Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: June 18, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Takahiro Sugimoto, Shinkichi Suzuki, Hiroki Sakamoto, Masami Yamada, Minoru Nakamura, Makoto Kamata, Kenichiro Shimokawa, Masataka Murakami, Jinichi Yonemori, Takuto Kojima
  • CANDIDATE SITE EVALUATION SYSTEM AND CANDIDATE SITE EVALUATION METHOD
    Publication number: 20190130427
    Abstract: A candidate site evaluation system includes: an evaluator that evaluates suitability of a candidate site in a target area based on a candidate site evaluation model and a second map, the candidate site evaluation model being obtained as a result of machine learning using a first map that shows any area and position information indicating locations of one or more existing facilities of a predetermined business type in the any area and being for evaluating the candidate site for opening a facility of the predetermined business type, the second map showing the target area including the candidate site to be evaluated; and an output unit that outputs a result of the evaluation.
    Type: Application
    Filed: October 23, 2018
    Publication date: May 2, 2019
    Inventors: Takahiro SUGIMOTO, Takashi TAJIMA, Masataka EJIMA
  • Nitrogen-containing heterocyclic compound
    Patent number: 10208046
    Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as medicaments such as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like, and the like. The present invention relates to a compound represented by the formula (I) wherein ring A is an optionally substituted 5- or 6-membered ring; R is a C1-6 alkyl group substituted by 1 to 5 halogen atoms; and X is —CH? or —N?, or a salt thereof.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: February 19, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Takahiro Sugimoto, Kenichiro Shimokawa, Takuto Kojima, Hiroki Sakamoto, Ikuo Fujimori, Minoru Nakamura, Masami Yamada, Masataka Murakami, Makoto Kamata, Shinkichi Suzuki